Discovery of a PCAF Bromodomain Chemical Probe

Angewandte Chemie - International Edition

Volumn 56, Issue 3, 2017, Pages 827-831

  Moustakim, Moses ^a,b   Clark, Peter G K ^c   Trulli, Laura ^d   Fuentes de Arriba, Angel L ^b   Ehebauer, Matthias T ^e   Chaikuad, Apirat ^f   Murphy, Emma J ^e   Mendez Johnson, Jacqui ^g   Daniels, Danette ^g   Hou, Chun Feng D ^h   Lin, Yu Hui ^h   Walker, John R ^h   Hui, Raymond ^h   Yang, Hongbing ^b   Dorrell, Lucy ^b   Rogers, Catherine M ^a   Monteiro, Octovia P ^a   Fedorov, Oleg ^a   Huber, Kilian V M ^a   Knapp, Stefan ^f   Heer, Jag ⁱ   Dixon, Darren J ^b   Brennan, Paul E ^a,e   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c SIMON FRASER UNIVERSITY   (Canada)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f GOETHE UNIVERSITY   (Germany)

^g PROMEGA CORPORATION   (United States)

^h Structural Genomics Consortium   (Canada)

ⁱ UCB PHARMA   (Belgium)

Author keywords

bromodomains; chemical probes; epigenetics; medicinal chemistry; structure based design

Indexed keywords

AMINO ACIDS; CELLS; CYTOLOGY; DRUG PRODUCTS; PROBES;

BROMODOMAINS; CHEMICAL PROBES; EPIGENETICS; MEDICINAL CHEMISTRY; STRUCTURE-BASED DESIGNS;

CRYSTAL STRUCTURE;

AZO COMPOUND; HISTONE ACETYLTRANSFERASE PCAF; HYDRALAZINE; P300-CBP-ASSOCIATED FACTOR;

ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG DEVELOPMENT; MOLECULAR PROBE; PHARMACOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

AZO COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HYDRALAZINE; MOLECULAR PROBES; MOLECULAR STRUCTURE; P300-CBP TRANSCRIPTION FACTORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85007227808     PISSN: 14337851     EISSN: 15213773     Source Type: Journal    
DOI: 10.1002/anie.201610816     Document Type: Article

References (46)

1. C. H. Arrowsmith, J. E. Audia, C. Austin, et al., Nat. Chem. Biol. 2015, 11, 536–541;
2. C. H. Arrowsmith, C. Bountra, P. V. Fish, et al., Nat. Rev. Drug Discovery 2012, 11, 384–400;
3. P. Filippakopoulos, S. Knapp, Nat. Rev. Drug Discovery 2014, 13, 337–356.
4. http://www.thesgc.org/chemical-probes.
5. P. Filippakopoulos, J. Qi, S. Picaud, et al., Nature 2010, 468, 1067–1073;
6. J. M. Garnier, P. P. Sharp, C. J. Burns, Expert Opin. Ther. Pat. 2014, 24, 185–199.
7. N. H. Theodoulou, N. C. O. Tomkinson, R. K. Prinjha, et al., ChemMedChem 2016, 11, 477–487;
8. M. Moustakim, P. G. K. Clark, D. A. Hay, et al., Med. Chem. Commun. 2016, 7, 2246–2264.
9. B. S. Gerstenberger, J. D. Trzupek, C. Tallant, et al., J. Med. Chem. 2016, 59, 4800–4811;
10. P. Bamborough, H. A. Barnett, I. Becher, et al., ACS Med. Chem. Lett. 2016, 7, 552–557;
11. J. Bennett, O. Fedorov, C. Tallant, et al., J. Med. Chem. 2016, 59, 1642–1647;
12. A. Unzue, M. Xu, J. Dong, et al., J. Med. Chem. 2016, 59, 1350–1356;
13. C. L. Sutherell, C. Tallant, O. P. Monteiro, et al., J. Med. Chem. 2016, 59, 5095–5101;
14. W. S. Palmer, G. Poncet-Montange, G. Liu, et al., J. Med. Chem. 2016, 59, 1440–1454;
15. W. Palmer, P. Jones, G. Liu, et al., University of Texas System, USA, 2016, p. 166;
16. L. J. Martin, M. Koegl, G. Bader, et al., J. Med. Chem. 2016, 59, 4462–4475;
17. T. D. Crawford, V. Tsui, E. M. Flynn, et al., J. Med. Chem. 2016, 59, 5391–5402;
18. O. B. Cox, T. Krojer, P. Collins, et al., Chem. Sci. 2016, 7, 2322–2330;
19. P. Chen, A. Chaikuad, P. Bamborough, et al., J. Med. Chem. 2016, 59, 1410–1424;
20. A. Chaikuad, S. Lang, P. E. Brennan, et al., J. Med. Chem. 2016, 59, 1648–1653;
21. P. Bamborough, C. w. Chung, E. H. Demont, et al., Angew. Chem. Int. Ed. 2016, 55, 11382–11386;
22. Angew. Chem. 2016, 128, 11554–11558.
23. A. J. Bannister, T. Kouzarides, Nature 1996, 384, 641–643;
24. V. V. Ogryzko, R. L. Schiltz, V. Russanova, et al., Cell 1996, 87, 953–959.
25. L. Kruidenier, K. Lee, D. F. Tough, et al.Group LimitedUK, Glaxo, 2014, p. 38;
26. B. K. Albrecht, A. Cote, T. Crawford, et al.Inc., USAInc., USA, Genentech, Constellation Pharmaceuticals, 2016, p. 179;
27. B. K. Albrecht, A. Cote, T. Crawford, et al.Inc., USAInc. USA, Genentech, Constellation Pharmaceuticals, 2016, p. 95.
28. S. Mujtaba, Y. He, L. Zeng, et al., Mol. Cell 2002, 9, 575–586;
29. V. C. Quy, S. Pantano, G. Rossetti, et al., Biology 2012, 1, 277–296;
30. Q. Wang, R. Wang, B. Zhang, et al., MedChemComm 2013, 4, 737–740;
31. A. Dorr, V. Kiermer, A. Pedal, et al., EMBO J. 2002, 21, 2715–2723.
32. M.-M. Zhou, G. Gerona-Navarro, Y. Rodriguez-Fernandez, et al., Icahn School of Medicine at Mount Sinai, USA, 2015, p. 87.
33. L. R. Vidler, N. Brown, S. Knapp, et al., J. Med. Chem. 2012, 55, 7346–7359.
34. A. J. N. M. Bastiaansen, M. M. Ewing, H. C. de Boer, et al., Arterioscler. Thromb. Vasc. Biol. 2013, 33, 1902–1910;
35. W.-G. Deng, Y. Zhu, K. K. Wu, Blood 2004, 103, 2135–2142.
36. P. Hu, X. Wang, B. Zhang, et al., ChemMedChem 2014, 9, 928–931.
37. B. K. Albrecht, D. J. Burdick, A. Cote, et al.Inc., USAInc. USA, Genentech, Constellation Pharmaceuticals, 2016, p. 117.
38. http://www.thesgc.org/chemical-probes/Bromosporine;
39. S. Picaud, K. Leonards, J.-P. Lambert, et al., Sci. Adv. 2016, 2, e1600760.
40. O. Fedorov, H. Lingard, C. Wells, et al., J. Med. Chem. 2014, 57, 462–476.
41. M. A. C. Neves, M. Totrov, R. Abagyan, J. Comput.-Aided Mol. Des. 2012, 26, 675–686.
42. P. L. Southwick, J. E. Anderson, J. Am. Chem. Soc. 1957, 79, 6222–6229.
43. https://www.chemaxon.com/library/pka-and-logp-property-prediction-and-training/.
44. A. L. Hopkins, C. R. Groom, A. Alex, Drug Discovery Today 2004, 9, 430–431.
45. T. Machleidt, C. C. Woodroofe, M. K. Schwinn, et al., ACS Chem. Biol. 2015, 10, 1797–1804.
46. R. E. Meléndez, W. D. Lubell, Tetrahedron 2003, 59, 2581–2616.